[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1005875A1 - N-oxycarbonyl substituted 5'- deoxy-5-fluorocytidines n- - Google Patents

N-oxycarbonyl substituted 5'- deoxy-5-fluorocytidines n-

Info

Publication number
HK1005875A1
HK1005875A1 HK98105008A HK98105008A HK1005875A1 HK 1005875 A1 HK1005875 A1 HK 1005875A1 HK 98105008 A HK98105008 A HK 98105008A HK 98105008 A HK98105008 A HK 98105008A HK 1005875 A1 HK1005875 A1 HK 1005875A1
Authority
HK
Hong Kong
Prior art keywords
radical
formula
deoxy
integer
protecting groups
Prior art date
Application number
HK98105008A
Other languages
English (en)
Inventor
Hideo Ishitsuka
Masanori Miwa
Isao Umeda
Motohiro Arasaki
Isami Kuruma
Chikako Murasaki
Nobuo Shimma
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1005875(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1005875A1 publication Critical patent/HK1005875A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK98105008A 1992-12-18 1998-06-05 N-oxycarbonyl substituted 5'- deoxy-5-fluorocytidines n- HK1005875A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92121538 1992-12-18

Publications (1)

Publication Number Publication Date
HK1005875A1 true HK1005875A1 (en) 1999-01-29

Family

ID=8210304

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98105008A HK1005875A1 (en) 1992-12-18 1998-06-05 N-oxycarbonyl substituted 5'- deoxy-5-fluorocytidines n-

Country Status (41)

Country Link
US (1) US5472949A (ja)
EP (1) EP0602454B1 (ja)
JP (1) JP2501297B2 (ja)
KR (1) KR100347218B1 (ja)
CN (1) CN1035617C (ja)
AT (1) ATE137244T1 (ja)
AU (1) AU671491B2 (ja)
BG (1) BG61485B1 (ja)
BR (1) BR9305089A (ja)
CA (1) CA2103324C (ja)
CZ (1) CZ284788B6 (ja)
DE (1) DE69302360T2 (ja)
DK (1) DK0602454T3 (ja)
EE (1) EE03086B1 (ja)
ES (1) ES2086856T3 (ja)
FI (1) FI112365B (ja)
GE (1) GEP20074251B (ja)
GR (1) GR3020286T3 (ja)
HK (1) HK1005875A1 (ja)
HR (1) HRP931430B1 (ja)
HU (2) HU218291B (ja)
IL (1) IL108000A0 (ja)
IS (1) IS4108A (ja)
LT (1) LT3115B (ja)
LV (1) LV10625B (ja)
MY (1) MY109282A (ja)
NO (1) NO300066B1 (ja)
NZ (1) NZ250414A (ja)
PH (1) PH30168A (ja)
PL (1) PL174100B1 (ja)
RO (1) RO112619B1 (ja)
RU (2) RU2458932C2 (ja)
SA (1) SA93140409B1 (ja)
SI (1) SI9300648B (ja)
SK (1) SK281403B6 (ja)
SV (1) SV1993000080A (ja)
TW (1) TW372239B (ja)
UA (1) UA39158C2 (ja)
UY (1) UY23697A1 (ja)
YU (1) YU49411B (ja)
ZA (1) ZA939293B (ja)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
NZ510504A (en) * 1998-09-25 2003-09-26 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
YU64602A (sh) * 2000-02-28 2005-06-10 Aventis Pharma S.A. Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
AU2001246863A1 (en) * 2000-04-11 2001-10-23 Sayuri Yamada Curcumin compositions
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
KR100730768B1 (ko) * 2000-08-09 2007-06-21 코오롱생명과학 주식회사 5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
GB0113374D0 (en) * 2001-06-04 2001-07-25 Jerram Clare Washing line umbrella
AU2003235761A1 (en) 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP1562601A1 (en) * 2002-11-15 2005-08-17 Warner-Lambert Company LLC Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
US20080026044A1 (en) * 2003-05-20 2008-01-31 Jonathan Lewis Combination Chemotherapy Comprising Capecitabine and a Liposomal Platinum Complex
DK1689404T3 (da) * 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
EP1706414B1 (en) * 2003-12-22 2008-07-23 F.Hoffmann-La Roche Ag Process for fluorocytidine derivatives
ATE504299T1 (de) 2005-02-03 2011-04-15 Gen Hospital Corp Verfahren zur behandlung von gefitinib- resistentem krebs
WO2006103187A2 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
BRPI0613783A2 (pt) 2005-07-18 2011-02-01 Bipar Sciences Inc tratamento de cáncer
CA2616008A1 (en) 2005-07-21 2007-01-25 Stefan Meuer Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
PT2343299E (pt) 2005-12-13 2016-02-26 Incyte Corp Pirrolo[2,3-b]piridinas e pirrolo[2,3-b]pirimidinas substituídas com heteroarilo como inibidores de janus quinase
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
BRPI0810067A2 (pt) * 2007-04-20 2014-10-21 Reddys Lab Ltd Dr Processo para a preparação de capecitabina
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
PL2173752T5 (pl) 2007-06-13 2022-12-05 Incyte Holdings Corporation Sole (r)-3-(4-(7h-pirolo(2,3-d)pirymidyn-4-ylo)-1h-pirazol-1-ilo)-3-cyklopentylopropanonitrylu inhibitora kinazy janusowej
US7842675B2 (en) * 2007-09-15 2010-11-30 Protia, Llc Deuterium-enriched capecitabine
US8741858B2 (en) * 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
KR20090122955A (ko) * 2008-01-03 2009-12-01 플러스 케미칼스, 에스.에이. 카페시타빈의 제조 방법
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
EP3135285B1 (en) 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
WO2010017163A1 (en) 2008-08-04 2010-02-11 Wyeth Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP2370414A4 (en) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr PREPARATION OF CAPECITABINE
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
US9211291B2 (en) 2009-04-06 2015-12-15 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
EP3643312A1 (en) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US20110021769A1 (en) * 2009-07-23 2011-01-27 Scinopharm Taiwan Ltd. Process for Producing Fluorocytidine Derivatives
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) * 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
PL3354652T3 (pl) 2010-03-10 2020-11-16 Incyte Holdings Corporation Piperydyn-4-ylowe pochodne azetydyny jako inhibitory JAK1
DK3117709T3 (en) 2010-03-12 2018-11-26 Genzyme Corp COMBINATION THERAPY FOR TREATMENT OF BREAST CANCER
JP5849312B2 (ja) 2010-05-21 2016-01-27 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤の局所製剤
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
UA113156C2 (xx) 2010-11-19 2016-12-26 Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
CN102558262A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种高纯度卡培他滨的制备方法
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
NZ749437A (en) 2013-03-06 2020-07-31 Incyte Holdings Corp Processes and intermediates for making a jak inhibitor
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
WO2015026818A1 (en) * 2013-08-20 2015-02-26 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
EP2883959A1 (en) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
CN103897006A (zh) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 一种卡培他滨异构体的制备方法
EP3151864B1 (en) 2014-06-09 2020-08-05 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
CN104530164A (zh) * 2014-12-31 2015-04-22 辰欣药业股份有限公司 一种卡培他滨的合成工艺
KR20160117060A (ko) 2015-03-31 2016-10-10 이승주 유아용 탁자
CN105646625B (zh) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 一种卡培他滨的制备方法
EP3565549B1 (en) 2017-01-09 2022-03-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
TR201702500A2 (tr) * 2017-02-20 2017-07-21 Anadolu Ueniversitesi Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3088287A1 (en) 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
ES2912469T3 (es) 2018-01-30 2022-05-26 Incyte Corp Procesos de elaboración de (1-(3-fluoro-2-(trifluorometilo)isonicotinil)piperidina-4-ona)
PT3773593T (pt) 2018-03-30 2024-06-25 Incyte Corp Tratamento da hidradenite supurativa com inibidores de jak
AU2020207026A1 (en) 2019-01-11 2021-07-29 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin C and method of manufacture
EP3999519A4 (en) 2019-07-17 2023-08-16 Nucorion Pharmaceuticals, Inc. CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS
JP2023523415A (ja) 2020-04-21 2023-06-05 リガンド・ファーマシューティカルズ・インコーポレイテッド ヌクレオチドプロドラッグ化合物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
EP4382093A1 (en) 2022-12-05 2024-06-12 a Fine House S.A. Oral suspensions comprising capecitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (en) * 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives

Also Published As

Publication number Publication date
FI112365B (fi) 2003-11-28
CN1094056A (zh) 1994-10-26
RU2493162C1 (ru) 2013-09-20
LV10625A (lv) 1995-04-20
CZ273193A3 (en) 1994-07-13
BR9305089A (pt) 1994-07-05
GEP20074251B (en) 2007-12-10
UY23697A1 (es) 1994-06-08
KR100347218B1 (ko) 2003-01-24
RU2458932C2 (ru) 2012-08-20
AU5069093A (en) 1994-06-30
NZ250414A (en) 1995-12-21
MY109282A (en) 1996-12-31
LV10625B (en) 1996-04-20
HU218291B (en) 2000-07-28
TW372239B (en) 1999-10-21
DE69302360D1 (de) 1996-05-30
IL108000A0 (en) 1994-04-12
BG61485B1 (bg) 1997-09-30
PL174100B1 (pl) 1998-06-30
LT3115B (en) 1994-12-27
CZ284788B6 (cs) 1999-03-17
NO934671L (no) 1994-06-20
PH30168A (en) 1997-01-21
AU671491B2 (en) 1996-08-29
HUT65757A (en) 1994-07-28
HU211965A9 (en) 1996-01-29
KR940014428A (ko) 1994-07-18
YU77993A (sh) 1996-10-18
BG98304A (bg) 1994-01-03
SA93140409B1 (ar) 2004-07-24
SK281403B6 (sk) 2001-03-12
CN1035617C (zh) 1997-08-13
HRP931430B1 (en) 1999-08-31
DE69302360T2 (de) 1996-10-31
ATE137244T1 (de) 1996-05-15
GR3020286T3 (en) 1996-09-30
JP2501297B2 (ja) 1996-05-29
SV1993000080A (es) 1996-01-26
YU49411B (sh) 2006-01-16
NO934671D0 (no) 1993-12-17
IS4108A (is) 1994-06-19
CA2103324C (en) 1997-12-23
CA2103324A1 (en) 1994-06-19
UA39158C2 (uk) 2001-06-15
NO300066B1 (no) 1997-04-01
HRP931430A2 (en) 1998-06-30
PL301541A1 (en) 1994-06-27
EP0602454A1 (en) 1994-06-22
SK144493A3 (en) 1994-10-05
DK0602454T3 (da) 1996-07-29
ES2086856T3 (es) 1996-07-01
FI935616A0 (fi) 1993-12-14
HU9303525D0 (en) 1994-04-28
ZA939293B (en) 1994-06-18
LTIP1627A (en) 1994-07-15
RO112619B1 (ro) 1997-11-28
US5472949A (en) 1995-12-05
EE03086B1 (et) 1998-04-15
JPH06211891A (ja) 1994-08-02
SI9300648B (sl) 2000-06-30
EP0602454B1 (en) 1996-04-24
FI935616A (fi) 1994-06-19
RU2135511C1 (ru) 1999-08-27
SI9300648A (en) 1994-09-30

Similar Documents

Publication Publication Date Title
GR3020286T3 (en) N-oxycarbonyl substituted 5'-deoxy-5-fluorocytidines.
RU93056196A (ru) N-карбонилзамещенные 5'-дезокси-5-фторцитидина
EG18944A (en) (Benzylidene) - Azolylmethylcycloalkane and use as fungicide
GR3007983T3 (ja)
GR3025293T3 (en) Spicamycin derivatives and the use thereof
HU9401976D0 (en) N,n'-substituted imidocarbonimidic diamides, pharmaceutical compositions containing them and use of these compounds aganst infection
CA2065978A1 (en) Organosilicon compounds containing (meth)acryloxy groups, their preparation and use
HU9202367D0 (en) Preparative for reducing blood pressure
EP0401715A3 (en) Aminoketone compounds

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20131130